Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 9/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27748727 | 1.00 | CCR1 (0.68) | CCR1NPC1TDP1DPP4MAPT | |
| SCHEMBL9501718 | 0.93 | CCR1 (0.60) | CCR1NPC1TDP1DPP4SMN1; SMN2 | |
| SCHEMBL26710742 | 0.93 | CCR1 (0.60) | CCR1NPC1TDP1DPP4SMN1; SMN2 | |
| SCHEMBL23157184 | 0.86 | NPC1 (0.55) | CCR1NPC1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL23157166 | 0.86 | NPC1 (0.55) | CCR1NPC1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL19692639 | 0.82 | CCR1 (0.54) | CCR1MAPTSMN1; SMN2CTSLCTSB | |
| SCHEMBL2158848 | 0.81 | CCR1 (1.00) | CCR1 | |
| SCHEMBL2158853 | 0.81 | CCR1 (1.00) | CCR1 | |
| SCHEMBL6446379 | 0.81 | ALDH1A1 (0.56) | CCR1MAPTSMN1; SMN2 | |
| SCHEMBL5711363 | 0.81 | ALDH1A1 (0.56) | CCR1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7959918-B2 | Methods for treating vascular disease | CEDARS-SINAI MEDICAL CENTER (US) | 2011-06-14 | — | — | US | claimed |
| US-20080286285-A1 | Methods for Treating Vascular Disease | CEDARS-SINAI MEDICAL CENTER (US) | 2008-11-20 | — | — | US | claimed |
| EP-1755670-A4 | METHODS FOR TREATING VASCULAR DISEASE | CEDARS SINAI MEDICAL CENTER (US) | 2008-07-02 | — | — | EP | claimed |
| EP-1755670-A2 | METHODS FOR TREATING VASCULAR DISEASE | Cedars-Sinai Medical Center (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005117975-A2 | METHODS FOR TREATING VASCULAR DISEASE | CEDARS-SINAI MEDICAL CENTER (US) | 2005-12-15 | — | — | WO | claimed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20220296628-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CUREVAC AG (DE) | 2022-09-22 | — | — | US | disclosed |
| EP-4013880-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CureVac AG (DE) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022053993-A2 | TREATMENTS FOR SARS-COV-2 INFECTION (COVID-19) | MYLAN LABORATORIES LIMITED (IN) | 2022-03-17 | — | — | WO | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090297533-A1 | CONTROLLED RELEASE IMMUNOMODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009132050-A2 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| CN-101474174-A | Application of N-[2-methyl-1-(pyrrolidine-1-carbonyl)-propyl]-3-phenyl propionamide in pharmacy | UNIV NANJING MEDICAL (CN) | 2009-07-08 | — | — | CN | disclosed |
| US-20080286285-A1 | Methods for Treating Vascular Disease | CEDARS-SINAI MEDICAL CENTER (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1755670-A4 | METHODS FOR TREATING VASCULAR DISEASE | CEDARS SINAI MEDICAL CENTER (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1755670-A2 | METHODS FOR TREATING VASCULAR DISEASE | Cedars-Sinai Medical Center (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005117975-A2 | METHODS FOR TREATING VASCULAR DISEASE | CEDARS-SINAI MEDICAL CENTER (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | CCR1 999/4885NPC1 189/4885TDP1 2449/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | CCR1 999/4885NPC1 189/4885TDP1 2449/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | CCR1 2730/4885NPC1 22/4885TDP1 1135/4885 |
| US-20220296628-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | TLR3, EIF2AK2, STING1 | CCR1 175/4885NPC1 2883/4885TDP1 1373/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | CCR1 999/4885NPC1 189/4885TDP1 2449/4885 |
| US-20090297533-A1 | CONTROLLED RELEASE IMMUNOMODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, CD74, TSLP | CCR1 127/4885NPC1 630/4885TDP1 1945/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | CCR1 999/4885NPC1 189/4885TDP1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.